-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback